About FDA
Cumulative number of technical analyses of postmarket device problems and performance completed
Cumulative FY 2013 Target: 131 by 9/30/2013
Dictionary: Postmarket device problems and performance issues constitute one of CDRH’s primary public health priorities. Typically, the appearance of such problems begins with many ambiguities and gaps in understanding exactly what happened in the reported incident(s) and, more importantly, why. The technical analyses are used to assess the hazards, determine the adequacy of proposed corrective actions, determine appropriate test methods, and develop case strategies for reported problems.
Information is current as of December 31, 2012
Fiscal Year - 2013
Cumulative FY 2013 Target: 131 by 9/30/2013
| Time | Cumulative Annual Target | Cumulative Number |
|---|---|---|
| Oct 2012 | 131 | 29 |
| Nov 2012 | 131 | 51 |
| Dec 2012 | 131 | 69 |
| Jan 2013 | 131 | TBD |
| Feb 2013 | 131 | TBD |
| Mar 2013 | 131 | TBD |
| Apr 2013 | 131 | TBD |
| May 2013 | 131 | TBD |
| Jun 2013 | 131 | TBD |
| Jul 2013 | 131 | TBD |
| Aug 2013 | 131 | TBD |
| Sep 2013 | 131 | TBD |
FY 2013 YTD: 69
Number of technical analyses of postmarket device problems and performance completed during the month
Cumulative FY 2013 Target: 131 by 9/30/2013
Fiscal Year - 2013
Cumulative FY 2013 Target: 131 by 9/30/2013
| Time | Target | Number |
|---|---|---|
| Oct 2012 | N/A | 29 |
| Nov 2012 | N/A | 22 |
| Dec 2012 | N/A | 18 |
| Jan 2013 | N/A | TBD |
| Feb 2013 | N/A | TBD |
| Mar 2013 | N/A | TBD |
| Apr 2013 | N/A | TBD |
| May 2013 | N/A | TBD |
| Jun 2013 | N/A | TBD |
| Jul 2013 | N/A | TBD |
| Aug 2013 | N/A | TBD |
| Sep 2013 | N/A | TBD |
FY 2013 YTD: 69
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
